Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Atypical hemolytic uremic syndrome

Atypical hemolytic uremic syndrome

Part of Anemia

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Atypical hemolytic uremic syndrome

7 trials tracked for Atypical hemolytic uremic syndrome.

7Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 7
  1. Phase 2 Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS Completed
  2. Phase 2 Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS Completed
  3. Phase 2 An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome Completed
  4. Phase 2 Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients Completed
  5. Phase 2 An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome Completed
  6. Phase 2 Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS Completed
Show 1 more trials
  1. Phase 2 Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Complement-targeted therapies show clinical activity in C3G and aHUS including 68% reduction in proteinuria
Drug Pipeline Meta-analysis
Complement-targeted therapies show clinical activity in C3G and aHUS including 68% reduction in proteinuria Newer therapies show promise for rare kidney and blood conditions
This narrative synthesis of 38 studies evaluates complement-targeted therapies for patients with C3G and aHUS. The review highlights positiv…
Newer treatments like iptacopan and pegcetacoplan may help manage serious kidney issues and blood disorders in specific patient groups.
Frontiers Aug 24, 2026
FDA Approves Epysqli (eculizumab-sbja) for PNH, aHUS, and gMG
Hematology FDA Approval
FDA Approves Epysqli (eculizumab-sbja) for PNH, aHUS, and gMG FDA approves new drug Epysqli for three rare blood and nerve conditions.
The FDA approved Epysqli (eculizumab-sbja) for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and gen…
The FDA approved Epysqli (eculizumab-sbja) for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myas…
FDA May 2, 2026